Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) Meeting Abstract
| Authors: | Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Dickinson, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; Salar, A.; Brody, J.; Leppä, S.; Berthier, A.; Kallemeijn, M.; Relf, J.; Chohan, S.; Lundberg, L.; Hutchings, M. |
| Abstract Title: | Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 3130 |
| Language: | English |
| ACCESSION: | WOS:001159740302239 |
| DOI: | 10.1182/blood-2023-173949 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
